Get the Stockscreener App
6.56
1.23%
0.08
Lifecore Biomedical Inc stock is traded at $6.56, with a volume of 126.66K.
It is up +1.23% in the last 24 hours and down -9.39% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
See More
Previous Close:
$6.48
Open:
$6.54
24h Volume:
126.66K
Relative Volume:
0.53
Market Cap:
$242.89M
Revenue:
$128.45M
Net Income/Loss:
$6.54M
P/E Ratio:
131.20
EPS:
0.05
Net Cash Flow:
$-8.79M
1W Performance:
+2.02%
1M Performance:
-9.39%
6M Performance:
+35.26%
1Y Performance:
-6.69%
1-Day Range:
$6.48
$6.67
1-Week Range:
$6.13
$6.67
52-Week Range:
$3.6793
$8.90
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LFCR
Lifecore Biomedical Inc
|
6.56 | 242.89M | 128.45M | 6.54M | -8.79M | 0.05 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-05-24 | Initiated | Craig Hallum | Buy |
| Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Stock (LFCR) Latest News
(LFCR) Technical Data - Stock Traders Daily
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Short Interest Update - MarketBeat
Lifecore Biomedical Announces Special Stockholder Meeting - The Manila Times
Lifecore Biomedical Calls Special Meeting to Vote on Preferred Stock Conversion Cap Removal - StockTitan
Jane Street Group LLC Increases Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - AccessWire
LFCR FY2025 EPS Forecast Boosted by Barrington Research - Defense World
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - AccessWire
LFCR FY2025 EPS Forecast Lifted by Barrington Research - MarketBeat
Paul Josephs Bought 3.1% More Shares In Lifecore Biomedical - Simply Wall St
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Lifecore Biomedical, Inc. (NASDAQ:LFCR) CEO Paul Josephs Acquires 17,000 Shares - MarketBeat
Geode Capital Management LLC Increases Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Barclays PLC Has $147,000 Stock Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical to sell multi-purpose 10-head isolator filler - MSN
Lifecore Biomedical Sells Excess Capital Equipment for $17M - Contract Pharma
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million - The Manila Times
Lifecore Biomedical Secures $17M Equipment Sale, Doubles Production Capacity with New Filler - StockTitan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Investors to Learn More About the Investigation - AccessWire
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
LFCR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Lifecore Biomedical, Inc. and Encourages Investors to Contact the Firm - AccessWire
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q2 2025 Earnings Call Transcript - MSN
Lifecore Biomedical’s (LFCR) “Equal Weight” Rating Reaffirmed at Stephens - Defense World
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out - AccessWire
Lifecore stock reaffirmed at Equal Weight at Stephens following Q2 results By Investing.com - Investing.com Canada
Lifecore Biomedical's (LFCR) "Equal Weight" Rating Reaffirmed at Stephens - MarketBeat
Further weakness as Lifecore Biomedical (NASDAQ:LFCR) drops 11% this week, taking three-year losses to 38% - Simply Wall St
US Stocks Poised To Open Higher As Futures Advance: Tesla, Bumble, Lifecore Bio In Focus - Benzinga
Lifecore Biomedical: Fiscal Q2 Earnings Snapshot - Midland Daily News
Lifecore Biomedical earnings beat by $0.02, revenue topped estimates - Investing.com UK
Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday - Benzinga
Lifecore Biomedical Inc (LFCR) Q2 2025 Earnings Call Highlights: Revenue Growth Amidst Rising ... By GuruFocus - Investing.com Canada
Earnings call transcript: Lifecore Biomedical Q2 2024 sees revenue growth, stock dips - Investing.com Australia
Lifecore Biomedical Reports Q2 Fiscal 2025 Results - TipRanks
Lifecore Biomedical Inc (LFCR) Q2 Fiscal 2025 Earnings: EPS Loss - GuruFocus.com
Lifecore Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 24, 2024 - Marketscreener.com
Lifecore Biomedical (LFCR) Reports Q2 Loss, Tops Revenue Estimates - MSN
Stocks to Watch: Lifecore Biomedical, Resources Connection - MarketWatch
Lifecore Biomedical Inc. (LFCR) reports earnings - Quartz
Lifecore Biomedical (NASDAQ:LFCR) Issues Earnings Results - MarketBeat
Lifecore Biomedical Swings to 2Q Loss Despite Higher Sales - MarketWatch
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update - The Manila Times
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate - The Bakersfield Californian
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Shares Acquired by State Street Corp - Defense World
Earnings To Watch: Lifecore Biomedical Inc (LFCR) Reports Q2 202 - GuruFocus.com
Earnings To Watch: Lifecore Biomedical Inc (LFCR) Reports Q2 2025 Result - Yahoo Finance
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):